Home > Riviste > Minerva Ginecologica > Fascicoli precedenti > Minerva Ginecologica 2014 Aprile;66(2) > Minerva Ginecologica 2014 Aprile;66(2):179-92

ULTIMO FASCICOLO
 

ARTICLE TOOLS

Estratti

MINERVA GINECOLOGICA

Rivista di Ostetricia e Ginecologia


Indexed/Abstracted in: EMBASE, PubMed/MEDLINE, Scopus, Emerging Sources Citation Index


eTOC

 

  FOCUS SUI DISTURBI OVARICI


Minerva Ginecologica 2014 Aprile;66(2):179-92

lingua: Inglese

New paradigms in the surgical and adjuvant treatment of ovarian cancer

Hodeib M., Eskander R. N., Bristow R. E.

Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, The University of California, Irvine, Orange, CA, USA


PDF  


Advanced stage epithelial ovarian cancer is difficult to treat. Despite advances in surgical resection and adjuvant chemotherapy the majority of patients suffer from disease recurrence. In an effort to improve oncologic outcomes, including progression free and overall survival, novel surgical paradigms and chemotherapeutic techniques have emerged over the past decade. An emphasis has been placed on achieving maximal surgical cytoreduction (defined as no visible residual disease) at completion of surgery, in combination with intra-peritoneal (IP) chemotherapy, as well as hyperthermic IP chemotherapy (HIPEC). This review article will discuss the evolution of surgical cytoreduction in the treatment of advanced stage epithelial ovarian cancer, as well as the development of adjuvant treatments that increasingly utilize the biologic advantage provided by microscopic residual disease.

inizio pagina

Publication History

Per citare questo articolo

Corresponding author e-mail

Eskander@uci.edu